ReviewNew biotechnology2011
Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology.
Review in New biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 81 citations in OpenAlex.
- Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs.Transplantation · 2017Trial
- Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail.Toxins · 2026Article
- MtrE Loop2-specific multiple antigenic peptide vaccine and monoclonal antibody confer complement-dependent protection against Neisseria gonorrhoeae.NPJ vaccines · 2026Article
- Novel broadly reactive monoclonal antibody protects againstInfection and immunity · 2025Article
- Therapeutic efficacy of SipD/LptD-specific IgY entrapped in alginate nanoparticles againstHeliyon · 2024Article
- Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models.Nature communications · 2024Article
- Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections.Vaccines · 2022Review
- Review
- Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Development of New Strategies for Malaria Chemoprophylaxis: From Monoclonal Antibodies to Long-Acting Injectable Drugs.Tropical medicine and infectious disease · 2022Review
- Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.Toxicology and applied pharmacology · 2022Article
- Nanomaterials in the Management of Gram-Negative Bacterial Infections.Nanomaterials (Basel, Switzerland) · 2021Review
- The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants.Antioxidants (Basel, Switzerland) · 2021Review
- COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.International immunopharmacology · 2021Review
- [Monoclonal antibodies for anti-infective therapy].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Convalescent plasma - this is no time for competition.Transfusion · 2020Review
- Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7.Infection and immunity · 2020Article
- Reassessing therapeutic antibodies for neglected and tropical diseases.PLoS neglected tropical diseases · 2020Review
- Review
- Monoclonal antibodies as anti-infective products: a promising future?Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody preparations have a long history of providing protection from infectious diseases. Although antibodies remain the only natural host-derived defense mechanism capable of completely preventing infection, as products, they compete against inexpensive therapeutics such as antibiotics, small molecule inhibitors and active vaccines. The continued discovery in the monoclonal antibody (mAb) field of leads with broadened cross neutralization of viruses and demonstrable synergy of antibody with antibiotics for bacterial diseases, clearly show that innovation remains. The commercial success of mAbs in chronic disease has not been paralleled in infectious diseases for several reasons. Infectious disease immunotherapeutics are limited in scope as endemic diseases necessitate active vaccine development. Also, the complexity of these small markets draws the interest of niche companies rather than big pharmaceutical corporations. Lastly, the cost of goods for mAb therapeutics is inherently high for infectious agents due to the need for antibody cocktails, which better mimic polyclonal immunoglobulin preparations and prevent antigenic escape. In cases where vaccine or convalescent populations are available, current polyclonal hyperimmune immunoglobulin preparations (pIgG), with modern and highly efficient purification technology and standardized assays for potency, can make economic sense. Recent innovations to broaden the potency of mAb therapies, while reducing cost of production, are discussed herein. On the basis of centuries of effective use of Ab treatments, and with growing immunocompromised populations, the question is not whether antibodies have a bright future for infectious agents, but rather what formats are cost effective and generate safe and efficacious treatments to satisfy regulatory approval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.